Alteration of p16 and p15 genes in common epithelial ovarian tumors. 1997

M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
Department of Obstetrics and Gynecology, Osaka University Medical School, Suita, Japan.

We have examined the roles of 2 putative tumor-suppressor genes, the p16 and p15 inhibitor-of-cyclin-dependent-kinase genes, in the most commonly occurring epithelial tumors of the human ovary. Expression of p16 mRNA, examined by RT-PCR, was significantly reduced in 15 of the 48 tumors. Aberrant expression of p16 protein, detected by immunohistochemistry, occurred in 22 of 60 tumors, more frequently in low-grade tumors, and had significant correlation with low p16 mRNA expression. Hypermethylation of a site within the 5'-CpG island of the p16 gene was significantly associated with loss of p16 mRNA and protein expression. Homozygous gene deletion, evaluated by differential PCR analysis, was found in 2 tumors for the p16 gene and in 1 tumor for the p15 gene among 70 ovarian tumors examined. PCR-SSCP analysis detected point mutations in p16 in 4 tumors and in p15 in 1 tumor. One was a 38-bp deletion, from codons 48 to 60, in a mucinous tumor of low malignant potential; another was a non-sense mutation in codon 60 in a mucinous adenocarcinoma. The remaining 2 mutations were mis-sense mutations, one in codon 58 and the other in codon 60, in 2 endometrioid adenocarcinomas. We conclude that inactivation of p16, by loss of p16 mRNA and protein expression as a consequence of hypermethylation of the 5'-CpG island, rather than by gene deletion or point mutation, may play an important role in the genesis of human ovarian epithelial tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002288 Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed) Carcinoma, Colloid,Carcinoma, Mucinous,Adenocarcinomas, Mucinous,Carcinomas, Colloid,Carcinomas, Mucinous,Colloid Carcinoma,Colloid Carcinomas,Mucinous Adenocarcinoma,Mucinous Adenocarcinomas,Mucinous Carcinoma,Mucinous Carcinomas
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain

Related Publications

M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
December 1994, Cancer research,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
October 2015, Toxicology and industrial health,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
October 1995, Journal of the National Cancer Institute,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
July 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
December 1996, International journal of cancer,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
September 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
June 2002, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
November 2000, Gynecologic oncology,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
February 1996, Cancer genetics and cytogenetics,
M Fujita, and T Enomoto, and T Haba, and R Nakashima, and M Sasaki, and K Yoshino, and H Wada, and G S Buzard, and N Matsuzaki, and K Wakasa, and Y Murata
April 1997, Blood,
Copied contents to your clipboard!